Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors

Drug Metabolism and Disposition

Volumn 35, Issue 3, 2007, Pages 340-344

  Weiss, Johanna ^a   Theile, Dirk ^a   Ketabi Kiyanvash, Nahal ^a   Lindenmaier, Heike ^a   Haefeli, Walter Emil ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DELAVIRDINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ANIMAL CELL; ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION;

ANIMALS; ANTI-HIV AGENTS; CELL LINE; DOGS; HUMANS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33847366629     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.012765     Document Type: Article

References (30)

1. Bachmeier CJ, Spitzenberger TJ, Elmquist WF, and Miller DW (2005) Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm Res (NY) 22:1259-1268.
2. Bogman K, Erne-Brand F, Alsenz J, and Drewe J (2003) The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J Pharm Sci 92:1250-1261.
3. Borst P, Evers R, Kool M, and Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302.
4. Dasgupta A and Okhuysen PC (2001) Pharmacokinetic and other drug interactions in patients with AIDS. Ther Drug Monit 23:591-605.
5. de Maat MMR, Ekhart GC, Huitema ADR, Koks CHW, Mulder JW, and Beijnen JH (2003) Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 42:223-282.
6. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G, and Haefeli WE (2004) Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 76:73-84.
7. Eagling VA, Back DJ, and Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194.
8. Evers R, Cnubben NHP, Wijnholds J, van Deemter L, van Bladeren PJ, and Borst P (1998a) Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett 419:112-116.
9. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude Elferink RPJ, Baas F, Schinkel AH, et al. (1998b) Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Investig 101:1310-1319.
10. Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, and Backman JT (2006) Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 98:79-85.
11. Gutmann H, Fricker G, Drewe J, Toeroek M, and Miller DS (1999) Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 56:383-389.
12. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, and Schinkel AH (2002) Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16:2276-2278.
13. Janneh O, Owen A, Chandler B, Hartkoorn RC, Hart CA, Bray PG, Ward SA, and Back DJ (2005) Modulation of the intracellular accumulation of saquinavir in peripheral blood mono-nuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 19:2097-2102.
14. Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, and Back DJ (2001) P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 15:1353-1358.
15. Kearney BP, Flaherty JF, and Shah J (2004) Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 43:595-612.
16. Kearney BP, Sayre JR, Flaherty JF, Chen SS, Kaul S, and Cheng AK (2005) Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J Clin Pharmacol 45:1360-1367.
17. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JML, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, et al. (1999) MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96:6914-6919.
18. Kotb R, Vincent I, Dulioust A, Peretti D, Taburet AM, Delfraissy JF, and Goujard C (2006) Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Haematol 76:269-271.
19. Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, and Granneman GR (1999) Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos 27:902-908.
20. Lindenmaier H, Becker M, Haefeli WE, and Weiss J (2005) Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2). Drug Metab Dispos 33:1576-1579.
21. Malaty LI and Kuper JJ (1999) Drug interactions of HIV protease inhibitors. Drug Saf 20:147-169.
22. Mikus G, Schowel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, Burhenne J, Weiss J, Thomsen T, and Haefeli WE (2006) Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 80:126-135.
23. Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, and von Moltke LL (2005) Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 33:764-770.
24. Piscitelli SC and Gallicano KD (2001) Interactions among drugs for HIV and opportunistic infections. N Engl J Med 344:984-986.
25. Profit L, Eagling VA, and Back DJ (1999) Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 13:1623-1627.
26. Ray AS, Olsen L, and Fridland A (2004) Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenfovir. Antimicrob Agents Chemother 48:1089-1095.
27. Sankatsing SU, Beijnen JH, Schinkel AH, Lange JMA, and Prins JM (2004) P-glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother 48:1073-1081.
28. Schinkel AH and Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29.
29. Weiss J and Haefeli WE (2006) Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values. Drug Metab Dispos 34:203-207.
30. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, and Braden G (2006) Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 42:283-290.